Text Size
275 studies found for:    biogen | biogen

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
4 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
5 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
6 Recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Intervention: Biological: BIIB033
7 Recruiting ATLAS - Anti-Tweak in Lupus Nephritis Patients
Condition: Lupus Nephritis
Interventions: Drug: BIIB023;   Drug: Placebo
8 Completed
Has Results 		Natalizumab High Titer Immunogenicity and Safety
Condition: Multiple Sclerosis
Intervention: Drug: natalizumab
9 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
10 Recruiting Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010
Conditions: Painful Lumbar Radiculopathy;   Healthy
Interventions: Biological: BG00010;   Drug: Placebo
11 Recruiting An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012
12 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
13 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
14 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
15 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
16 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
17 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
18 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
19 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
20 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years